Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
I think it is very possible. Would be nice... :)
Yes we do Little Ricky.
"The initiation of these three clinical trials is dependent on the approval for use of the Cell-in-a-Box® live cell encapsulation facility that has been constructed in Bangkok, Thailand, by our partner, Austrianova. This facility must be approved as being compliant with current Good Manufacturing Practices (cGMP) standards by Thailand’s and Australia’s drug regulatory authorities as well as by the U.S. FDA."
Ken Waggoner
http://www.biomedreports.com/20150518222991/qaa-with-pharmacyte-ceo-kenneth-l-waggoner-on-pmcbs-new-direction.html
Nice link!
:). Thanks Jimmy Joe. GLTU
$PMCB
Hey, Jimmy Joe, good to see you still around. I don't have any additional insight other than what we know. What did give me additional peace of mind was the special kind of cotton used and the fact that Dr. Gunzburg said it would take at least 7 years for another entity to figure out how to make the device. However, I do think we will need extensions so getting trials going will help and certainly the ODD sets us up for an extension as well.
The upside is worth the risk for sure, IMO. I love this technology and our medical team is amazing and very familiar working with it as well. Additionally, our CEO is an attorney who appears very driven to get Cell in a Box to market. An added motivation for him, I'm sure, is the fact that his father died of Pancreatic Cancer.
I am holding confidently, JJ. All signs point to "full speed ahead" IMO. That is also why I'd like to see this stock not being manipulated and shorted constantly. The continuous flipping hurts our efforts, IMO. Believers need to hold. This will strengthen the PPS which will help fund our MANY efforts here.
I was hoping the change to AST would cause a change in what folks could get way with. The fact that the SEC works closely with AST bodes well for long term shareholders.
Dr. Manuel Hidalgo joins PharmaCyte SAB
July 17, 2015 by Shane Matte
Dr.. Manuel Hidalgo, one of Europe’s leading clinical and laboratory investigators in the field of pancreatic cancer, has joined PharmaCyte Biotech’s (OTCQB:PMCB) scientific advisory board.
In a statement, CEO, Kenneth Waggoner, said Dr. Hidalgo’s “interest in our novel treatment is particularly rewarding to all of us and strongly supports our steadfast belief that it will ultimately become a breakthrough in the future treatment of pancreatic cancer.”
He said Dr. Hidalgo’s interest in using the company’s Cell-in-a-Box technology to develop treatments for other solid tumors, like liver cancer, means that his addition to our scientific advisory board could well pave the way towards a fruitful future for PharmaCyte Biotech.
In 2009, Dr. Hidalgo joined the Spanish National Cancer Research Centre where he currently heads the Gastrointestinal Cancer Clinical Research Unit. He is also a co-founder and chairman of the international Pancreatic Cancer Research Team.
Dr. Hidalgo has participated in the clinical development of more than 30 novel anticancer agents, including studies for the current gold standard to treat advanced pancreatic cancer, the combination chemotherapy of gemcitabine and Abraxane.
He also led the early clinical trials of Torisel, approved for use against advanced kidney cancer, and Tarceva, approved for use against advanced non-small cell lung cancer as well against advanced pancreatic cancer when used in combination with gemcitabine.
Dr. Hidalgo said Cell-in-Box plus low dose ifosfamide combination chemotherapy might well prove to be of great value for the development of new treatments for pancreatic and other solid tumor cancers.
http://biotuesdays.com/2015/07/17/dr-manuel-hidalgo-joins-pharmacyte-sab/
Thanks Golf, appreciate it... :)
"The fact that Dr. Hidalgo is a bit of a hero in the oncology world doesn't hurt either. By the nature of his work, he has to have an impressive rolodex that may come in handy in the future.".....
http://www.smallcapnetwork.com/PharmaCyte-Biotech-Just-Added-Another-All-Star-to-Its-Roster-PMCB/s/via/10/article/view/p/mid/2/id/235/
Very nice post Pete. Now that is an oncologist team!
"The technology (Cell in a Box) has broad application, and I look forward to working with PharmaCyte Biotech to develop the technology and expand its application.”
Dr. Hidalgo
Jz, I see a team of world renowned oncologists, all with experience using Cell in a Box(R) technology, coming on board. All of whom have connections with many other bios. I like what we are cooking up here. A great recipe for success. Lots of PROS here.
Rome was not built in a day...
“Games are won by players who focus on the playing field –- not by those whose eyes are glued to the scoreboard.”
Warren Buffett
The PPS can change in an instant and I believe that the team we are building is designed to do just that. This is not a play for the impatient, those who expect the PPS to rise with every PR. PRs are for information purposes only. The value of the information will be realized when the game is won. Right now, we are focusing on the playing field, not the scoreboard. Not a game for the impatient, just like baseball. :)
And if I believed we were not on track for greatness, I would spend my time elsewhere. I don't see a reason to waste my time on anything that doesn't show promise. I have believed in this technology for over a year now and I like that we are taking the steps to see this technology to market. Adding another renowned oncologist is another major milestone, IMO.
But, to each his own. I am holding this one for sure...
Yes, it is very telling that liver cancer is mentioned in today's PR. And note, it is the doctor who sees the additional uses for CiaB technology.
"Dr. Hidalgo’s interest in using our Cell-in-a-Box® technology to develop treatments for other solid tumors, like liver cancer, means that his addition to our Scientific Advisory Board could well pave the way towards a fruitful future for PharmaCyte Biotech.”
I guess what matters is what is thought to be important. The amazing team we are putting together is very important and if Dr Hidalgo is joining us, and he works very closely with Dr Von Hoff, our results must be good, otherwise, why would he join?
It makes sense to me that he would not be joining us if he didn't see potential in Cell in a Box technology. I understand not everyone believes in this product, but I am glad to see those that have extensive experience in treating pancreatic cancer are interested.
I will follow the experts. Just sayin...
Pretty evident preclinical trials showed good results. Dr Hidalgo co created the PCRT with Dr Von Hoff so he has first hand knowledge and has decided to join us. Amazing news!
Thanks Bill. Do you watch Level 2?
Pharmacytebiotech.com
A great place to start your DD.
http://www.pharmacytebiotech.com/nuvilex-announces-name-change-pharmacyte-biotech/
It is really impossible to predict the future. You can plan for it but predicting it can lead to misinformation.
“Forecasts may tell you a great deal about the forecaster; they tell you nothing about the future.”
Warren Buffett
PharmaCyte Biotech's Cell-in-a-Box Technology Makes Good Cancer Drugs Better
BONITA, CA, Jul 13, 2015 (Marketwired via COMTEX) -- While many biotech companies are working on new oncology drugs, what's often unappreciated about cancer treatments is how a key improvement in the way drugs are delivered can make a world of difference in their effectiveness. A young and enterprising biotechnology R&D firm called PharmaCyte Biotech (otcqb:PMCB) understands this, and has not only embraced the benefit of improved dosing methods, but has developed a breakthrough that could change the way we altogether think about pharmaceuticals.
The technology is called Cell-in-a-Box®. Just as the trademarked name suggests, it's a way to encapsulate a variety of types of living cells in a tiny container -- a "box," so to speak - that can be deposited by the dozens in an area of the body where they'll drive a therapeutic benefit. In fact, roughly the size of the head of a pin, these encapsulations can be surgically deposited without the patient even realizing they're there.
The possibilities of such an approach are virtually limitless, though PharmaCyte has decided to first focus on developing the technology as a means of using a drug called ifosfamide, or Ifex, to combat pancreatic cancer... a notoriously difficult cancer to treat.
Ifosfamide is recognized as an effective therapy for pancreatic cancer patients. The drug, however, is also known to frequently create harsh side effects that can become intolerable in and of themselves. For that reason, oncologists often prefer a combination of Abraxane®, from Celgene Corporation, with gemcitabine, from Eli Lilly, to treat the disease. Gemcitabine in combination with Tarceva, made by Roche Holding subsidiary Genentech, is also a preferred therapy.
Ifosfamide could still be a viable choice, however, were the dosing whittled down to levels that didn't create difficult side effects but also didn't hinder its effectiveness. That's where PharmaCyte's Cell-in-a-Box could change the complexion of not just the war on cancer, but of all medicine.
Many drugs have a relatively short half-life, particularly once put into a human body. A person's own immune system and chemistry can begin breaking down drug molecules almost immediately, destroying many of them before they ever reach their intended destination.
The solution in most cases is simply to up the dosage so enough of an intact drug will eventually arrive at the point of the disease. In cases where adverse side effects are significant though -- as they can be with ifosfamide -- bigger doses aren't a viable option.
Cell-in-a-Box solves that problem by activating ifosfamide, a prodrug, near the pancreas to ensure maximum effectiveness with minimal dosing.
The science may be simple, but it's also brilliant. Rather than injecting ifosfamide in its final, fragile form, an ifosfamide prodrug that's in a much tougher, durable form is injected into the pancreatic cancer patient. Then, rather than in the liver where many drugs are processed and activated, this prodrug is converted to an active form of ifosfamide in the bloodstream right at the site of the tumor as it passes over the Cell-in-a-Box capsules with the cell inside that are capable of activating this prodrug.
PharmaCyte Biotech has achieved compelling results with this targeted chemotherapy approach too.
In a phase 1/2 trial examining the benefit of the Cell-in-a-Box delivery of ifosfamide versus the results gemcitabine would be able to achieve alone, the Cell-in-a-Box approach improved the median survival time from 28 to 44 weeks. Equally impressive is the fact that the number of one-year survivors increased from 18 percent to 36 percent of the study's patients. Even more encouraging are the lack of side effects witnessed with the lower doses of ifosfamide that are used in this approach.
The company reports it's aiming to begin phase 2b clinical trials of Cell-in-a-Box in conjunction with low doses of ifosfamide in Australia sometime in the third quarter of this year, which will compare it to the combination of Abraxane plus gemcitabine.
Pancreatic cancer is just the beginning, however. PharmaCyte is looking to develop a similar approach as a treatment for brain tumors, and the company is even aiming to encapsulate insulin-producing cells that could offer a breakthrough solution for type 1 diabetics.
The SEC does not have the resources to monitor violations on the OTC with regularity. Now we have a transfer agent that is going to be monitoring our trade action and working with the SEC to look for fraud. That is very significant for me as a shareholder.
I also have every confidence that PharmaCyte Biotech will prove Cell in a Box(R) is revolutionary.
Would never happen. AST is the #1 transfer agent. They obviously know what they are doing. Smoke and mirrors. :)
Yep, it is a very big deal to have our shares managed by the best. Great DD!
Thanks Bill. Great DD. They will be managing our shares which is huge within itself.
You know one of the links dealerschool posted about American Stock Transfer & Trust Company was an article about how they were ranked the #1 Agent in the industry.
We just jumped from our shares being managed by an OTC/Grey Market transfer agent, Signature Stock Transfer, to being managed by a Fortune 100 transfer agent. Suffice it to say, our CEO is pretty BA. If you know what I mean. :)
Also, I wonder if Liquard might have put in a good word for us? Hmmmm
http://www.otcmarkets.com/research/service-provider/Signature-Stock-Transfer--Inc-?id=2227
http://finance.yahoo.com/news/pharmacyte-biotech-appoints-american-stock-132000177.html
http://www.businesswire.com/news/home/20111129006669/en/American-Stock-Transfer-Trust-Company-Ranked-1#.VZ9V5EpHarV
Nice DD dealerschool. Thanks...
Nice, Pete. Go $PMCB!
Ken Waggoner continues to be the catalyst for PMCBs success.
LMAO!
This provides some info on the roles of intermediaries and transfer agents. In just reading the overview for both, I gained a lot of insight to potential reasons for changing TAs. Certainly, after reading this information, I believe Liquard may have been instrumental in affecting the change.
https://www.ici.org/pdf/ppr_09_nav_relationships.pdf
PharmaCyte Biotech is Making Waves - Take the Hint (PMCB)
PharmaCyte Biotech Inc. (OTCMKTS:PMCB) is turning more and more heads. There has to be a reason, but more than that, there's apt to be a beneficial effect on the stock's price.Anybody who owns, or is thinking about owning, a stake in PharmaCyte Biotech Inc. (OTCMKTS:PMCB) will want to take a closer look at not one but two different news items that were posted today. One of them could be an important housekeeping item, and the other one is encouraging, though not for the reason it may seem on the surface.
For the unfamiliar, PharmaCyte Biotech is the developer of a novel drug-delivery technology called Cell-in-a-Box. Just as the trademarked name describes, this biotechnology puts living cells grown to perform a specific function into a container... about the size of the head of the pin. The "shell" is porous enough to let chemicals in and waste out, but not so porous that it allows a body's immune system to attack and kill the foreign cells. The show-stopper, however, is the durability of the Cell-in-a-Box capsules. They are designed to last indefinitely.
The end result is the ability to make certain cells and place them inside a body.
To date PharmaCyte Biotech has focused on using the Cell-in-a-Box platform to treat pancreatic cancer, and more recently it's beginning to develop a therapy for type 1 diabetes. In fact, with the ability to encapsulate insulin-producing cells, PMCB may well have the equivalent to a cure for debates. The company also has brain tumors on the radar, with the potential use of cannabinoids as the basis for the therapy. The sky's the limit, however, for how the biotechnology can be used.
Fast forward to today.
Though it won't affect the price of the stock or mean much in terms of the company's R&D, PharmaCyte will be using a new stock transfer agent as of tomorrow. The America Stock Transfer and Trust Company will be taking on those duties after today.
The other news from PharmaCyte Biotech today - news that might actually move the price of PMCB - is that it's now being given analytical coverage from SmallCap IR.
It's often an overlooked reality regarding small and micro cap companies, but one of the toughest challenges these outfits have is getting professional and retail investors to notice them. PMCB is being increasingly noticed, however, which is a good sign. And, the more it gets noticed, the easier it becomes for another to notice it. In that light, PharmaCyte Biotech may be about to hit a publicity critical mass.
To the extent it matters (which is quite a bit), SmallCap IR wasn't paid a penny by anyone to open its coverage of PMCB. Better yet, it initiated coverage with a buy rating. To read the report, visitors can go here: https://secure.blueoctane.net/forms/P8HV6VHHUN6N
With or without the SmallCap IR analytical coverage, though, PharmaCyte Biotech Inc. is quickly turning into one of the market's more compelling story stocks. It was also a big hit at the BIO International Convention in June, as well as at the Astrodrugs conference.
For more on Pharmacyte Biotech, visit the company website here.
http://www.smallcapnetwork.com/PharmaCyte-Biotech-is-Making-Waves-Take-the-Hint-PMCB/s/via/10/article/view/p/mid/3/id/554/
Bio, I think KW is demonstrating to all shareholders that he is very much interested in maximizing shareholder value. Take a look at the companies associated with each Transfer Agency. Our previous one, Signature Stock works primarily with Grey Market and OTCs. On the other hand, as KW mentioned, AST even manages some Fortune 100 companies. Good news, IMO.
http://www.otcmarkets.com/research/service-provider/Signature-Stock-Transfer--Inc-?id=2227
https://www.amstock.com/proxyservices/viewmaterials.asp#C
PharmaCyte Biotech Appoints American Stock Transfer as New Stock Transfer Agen
SILVER SPRING, Md., July 09, 2015 (GLOBE NEWSWIRE) -- PharmaCyte Biotech, Inc. (PMCB), a clinical stage biotechnology company focused on developing targeted treatments for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box®, announced today that, effective July 10, 2015, American Stock Transfer & Trust Company (“AST”) will replace Signature Stock Transfer as its stock transfer and dividend disbursing agent.
The Chief Executive Officer of PharmaCyte Biotech, Kenneth L. Waggoner, commented on PharmaCyte Biotech’s new stock transfer agent, “We are extremely pleased to announce that we have appointed AST to be our new stock transfer agent. We are confident that our partnership with this fine organization will provide our shareholders with superior customer service and support. In addition, it will enable us to have access to the industry’s leading management resources and will ensure us the highest quality of operational process that we believe will yield tangible financial benefits to PharmaCyte Biotech and its shareholders.”
AST and its affiliates are leading providers of registry services and technology to financial market participants around the globe. With over 40 years of experience, AST is known for providing a superior customer service experience, which is supported by ongoing investments to technology, people and service offerings. AST has premier in-house call centers, innovative software and processing systems that set the industry standard.
AST provides comprehensive stock transfer and employee plan services to over 2,800 public companies and maintains approximately 6,000 issues. AST’s clients are located throughout the United States and in over 22 foreign countries, ranging in size from initial public offerings to Fortune 100 companies. Founded in 1971 and headquartered in New York, AST provides clients around the globe with customized solutions to fit their specific needs along with access to the best systems, services, processes and products available today.
On and after July 10, 2015, all inquiries and correspondence related to stockholder records, transfer of shares, lost certificates, dividend checks or change of address requests should be directed to AST. If you have questions, please call AST at (800) 937-5449 or email AST at info@amstock.com. AST can also be contacted via mail at:
PharmaCyte Biotech Inc.
c/o American Stock Transfer & Trust Company, LLC
6201 15th Avenue
Brooklyn, NY 11219
On July 10, 2015, welcome letters with detailed information about AST will be mailed directly to all PharmaCyte Biotech registered shareholders with instructions on how to access their account through AST.
http://finance.yahoo.com/news/pharmacyte-biotech-appoints-american-stock-132000177.html
Thanks Golf, that is much appreciated. I believe very strongly in this company and always appreciated how much other longs helped with my own DD when I was new. :)
GLTU
Wow, Pete! Great job! I like the videos at the top. Nice...
Very respected writer/editor and all the achievements are fact... We have a very effective CEO.
Q&A with PharmaCyte CEO, Kenneth L. Waggoner on PMCB’s New Direction
By M.E. Garza, Editor BioMedReports.com
http://www.biomedreports.com/20150518222991/qaa-with-pharmacyte-ceo-kenneth-l-waggoner-on-pmcbs-new-direction.html
Additionally, since the article was written, as a result of contracting with PMCB for cannabis related treatments the Universityof Northern Colorado received DEA Schedule 1 approval.
http://www.otcmarkets.com/stock/PMCB/news/PharmaCyte-Biotech-s-Dr--Mark-Rabe-Discusses-the-Significance-of-Schedule-1-License-to-Company-s-Future-in-Cannabis-Research?id=107682
http://www.pharmacytebiotech.com/pharmacyte-biotech-advances-cannabinoid-research-with-schedule-1-license/
From the Q & A with Ken Waggoner.
Q: Can you describe some of the major milestones you’ve been able to accomplish since coming on board?
KENNETH: First and foremost, PharmaCyte Biotech has been completely transformed from a nutraceutical company into a pure biotechnology company. We are no longer in the nutraceutical business. Some of the other major milestones include the following:
The financial position of PharmaCyte Biotech has become the strongest in the Company’s history. We are virtually debt-free and have access to all of the necessary capital required to meet both our short-term and long-term financial commitments.
We are well underway in completing the necessary steps to commence three clinical trials using our Cell-in-a-Box® technology. The first will be a Phase 2b clinical trial of our pancreatic cancer treatment. Our pancreatic cancer treatment will be compared “head-to-head” with the current best available treatment for the disease. This treatment is the combination of gemcitabine with Celgene’s drug Abraxane®. We expect to begin this clinical trial in the third quarter of 2015.
We are also underway in completing preparations for two other clinical trials related to the “quality of life” of patients with advanced pancreatic cancer and other abdominal tumors. These clinical trials deal with treatments for the: (i) intractable and virtually untreatable pain about 20-25% of patients with advanced pancreatic cancer suffer from; and (ii) accumulation of fluid (knows as ascites) in the abdomen that is extremely uncomfortable for patients with pancreatic cancer and other abdominal tumors. Because ascites fluid can contain cancer cells and these cells can seed and form new tumors, oncologists must frequently remove ascites fluid from patients. This is costly and painful. There is no treatment on the market to slow down the accumulation of ascites fluid. We believe our treatment will. We expect to start both clinical trials late in the third quarter of 2015.
We commenced and concluded our first preclinical study (4 groups of tumor bearing mice) that was conducted by Translational Drug Development (TD2) in the U.S. to determine the ability of our treatment of Cell-in-a-Box® plus ifosfamide to delay the accumulation of malignant ascites fluid. An expanded study (12 groups of mice) is currently being conducted by TD2. This study is designed to further define the parameters that will be needed for our future clinical trial in this area.
Our treatment for advanced, inoperable pancreatic cancer was granted the Orphan Drug designation by the U.S. Food and Drug Administration (FDA) in December 2014. Granting of this designation means that PharmaCyte Biotech will receive 7 years of marketing exclusivity in the U.S. for its pancreatic cancer treatment and reduced taxes and assistance from the FDA in the further development of our treatment.
We obtained the worldwide rights to use a genetically modified cell that produces insulin on demand in direct proportion to the amount of glucose (sugar) in their surroundings. These rights were obtained from the University of Technology Sydney (UTS) where Prof. Ann Simpson, along with her colleagues at UTS, have spent years developing this unique cell line called “Melligen".
We have completed a study at the University of Veterinary Medicine Vienna (UVM) to determine if the Melligen cells have the propensity to form tumors in the body. The Melligen cells were found to be as “safe” as the genetically modified cells used in the previous clinical trials in pancreatic cancer in terms of potential tumor formation in the body over time. We have also begun studies to establish the parameters by which the Melligen cells can produce and store insulin in response to glucose levels in their surroundings.
Through a Collaborative Research Agreement with the Vorarlberg Institute for Vascular Investigation and Treatment in Austria, Dr. Eva-Maria Brandtner has been appointed our Director of Diabetes Program Development. Dr. Brandtner was responsible for studies with the Melligen cells during her previous tenure with our partner, Austrianova, as its Chief Scientist.
An international Diabetes Consortium has been established by PharmaCyte Biotech. The Diabetes Consortium brings together a global coalition of world class experts from various universities and institutions in several countries around the world. All 16 members of the Consortium are committed to developing a treatment for insulin-dependent diabetes using PharmaCyte Biotech’s Cell-in-a-Box® live-cell encapsulation technology combined with human non-pancreatic, insulin-producing cells.
Several contracts and Collaborative Research Agreements have been entered into with leading research universities, scientists, academics and institutions around the globe that will facilitate PharmaCyte Biotech’s development of its cancer and diabetes treatments.
We obtained the exclusive worldwide license from Austrianova to use the Cell-in-a-Box® live cell encapsulation technology in combination with compounds obtained or developed from constituents of Cannabis, known as cannabinoids, for the treatment of diseases and their related symptoms.
Progress is underway at the University of Northern Colorado in an attempt to identify a cell line that can be encapsulated using the Cell-in-a-Box® technology, which, in turn, can be used together with cannabinoid or cannabinoid-like prodrugs as treatment for deadly and difficult to treat cancers, such as brain cancer.
The company changed its name from Nuvilex, Inc. to PharmaCyte Biotech, Inc. to emphasize that it has fully transitioned from a nutraceutical company to a purely biotechnology company.
Significant changes have been made at the Board of Directors level, including a new member with major pharmaceutical experience being named as our first replacement Board member. Others members are in the final interview process, all of whom will be widely experienced in the life sciences.
http://www.biomedreports.com/20150518222991/qaa-with-pharmacyte-ceo-kenneth-l-waggoner-on-pmcbs-new-direction.html